Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC

Lung Cancer

Volumn 84, Issue 2, 2014, Pages 203-205

  Li, Shuai ^a   Zhou, Fangyu ^a   Ren, Shengxiang ^a   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Acquired resistance; Chemotherapy; EGFR TKI; NSCLC; Pemetrexed; Rechallenge

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; PEMETREXED; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUTAMIC ACID DERIVATIVE; GUANINE; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER RESISTANCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; DRUG RECHALLENGE; DRUG TOLERABILITY; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; GENETICS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MISSENSE MUTATION; NEOPLASM RECURRENCE, LOCAL; NUCLEOTIDE SEQUENCE; PATHOLOGY; RADIOGRAPHY; SECONDARY;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84899493745     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.02.010     Document Type: Article

References (8)

1. Gao G., Ren S., Li A., Xu J., Xu Q., Su C., et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer 2012, 131:E822-E829.
2. Sequist L.V., Yang J.C., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31(27):3327-3334.
3. Yang J.J., Chen H.J., Yan H.H., Zhang X.C., Zhou Q., Su J., et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer 2013, 79:33-39.
4. Goldberg S.B., Oxnard G.R., Digumarthy S., Muzikansky A., Jackman D.M., Lennes I.T., et al. Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to egfr tyrosine kinase inhibitors. Oncologist 2013, 18(11):1214-1220.
5. Oxnard G.R., Arcila M.E., Chmielecki J., Ladanyi M., Miller V.A., Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011, 17(17):5530-5537.
6. Hata A., Katakami N., Yoshioka H., Takeshita J., Tanaka K., Nanjo S., et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations. Cancer 2013 December, 119(24):4325-4332.
7. Bearz A., Talamini R., Rossoni G., Santo A., de Pangher V., Fasola G., et al. Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Res Notes 2012, 5(1):482.
8. Nagano T., Kim Y.H., Goto K., Kubota K., Ohmatsu H., Niho S., et al. Re-challenge chemotherapy for relapsed non-small-cell lung cancer. Lung Cancer 2010, 69(3):315-318.